Biocon Biologics
Dave Gibson is currently the Global Head of Business Development at Biocon Biologics, part of the Executive Leadership Team, with responsibilities including Mergers, Acquisitions, Divestments, Licensing, and Strategic Partnering. Prior to this, at GSK, Gibson held various senior positions in Business Development, Innovation, and Pharmaceutical Development, including leading the creation of Pharmaceutical Development Centres within the organization. Additionally, Gibson has served as an Advisory Board Member at University College Cork and a Mentor at HealthXL accelerator for Digital Health start-up companies. Gibson holds a degree in Biotechnology from Dublin City University.
This person is not in any offices
Biocon Biologics
8 followers
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Follow-us on Twitter: @BioconBiologics